Pharmacokinetic modelling of the interaction between St John's wort and ciclosporin A

Yuichi Murakami, Tomoaki Tanaka, Hideyasu Murakami, Masayuki Tsujimoto, Hisakazu Ohtani, Yasufumi Sawada

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Aims: St John's wort (SJW) decreases the blood concentration of ciclosporin A (CsA), which may result in allograft rejection. In addition, the time course of this interaction is not parallel with the administration of SJW. We aimed to develop a pharmacokinetic model to predict the time profile of blood CsA concentrations during and after the intake of SJW. Methods: We developed a pharmacokinetic model incorporating turnover of detoxicating proteins, with the assumption that the amount of detoxicating proteins is in inverse proportion to the ratio of trough blood concentration to daily dose (C/D ratio) of CsA. First, we collected time profiles of blood CsA during and after the intake of SJW from the literature. Next, we analysed the relationship between D/C ratio and the daily dose of SJW at steady state. Subsequently, the developed model was simultaneously fitted to the time profiles of C/D ratios by using a nonlinear least-squares method to obtain model parameters. Results: The model analysis revealed that the induction of the detoxicating proteins by SJW was saturable with an elimination rate constant of the detoxicating proteins (ke) of 4.72 month-1. Elimination half-life of the detoxicating proteins calculated from the ke value was 4.4 days, suggesting that the dose of CsA should be carefully monitored for up to 2 weeks after the cessation of SJW intake. Conclusions: The present model may provide additional information for use in identifying optimal dosage regimens of CsA during and after the intake of SJW to prevent an adverse drug interaction between CsA and SJW.

Original languageEnglish
Pages (from-to)671-676
Number of pages6
JournalBritish Journal of Clinical Pharmacology
Volume61
Issue number6
DOIs
Publication statusPublished - 2006 Jun
Externally publishedYes

Fingerprint

Cyclosporine
Pharmacokinetics
Proteins
Dilatation and Curettage
Least-Squares Analysis
Drug Interactions
Allografts
Half-Life

Keywords

  • Ciclosporin A
  • Dosage
  • Drug interaction
  • Pharmacokinetic model
  • St John's wort

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Pharmacokinetic modelling of the interaction between St John's wort and ciclosporin A. / Murakami, Yuichi; Tanaka, Tomoaki; Murakami, Hideyasu; Tsujimoto, Masayuki; Ohtani, Hisakazu; Sawada, Yasufumi.

In: British Journal of Clinical Pharmacology, Vol. 61, No. 6, 06.2006, p. 671-676.

Research output: Contribution to journalArticle

Murakami, Yuichi ; Tanaka, Tomoaki ; Murakami, Hideyasu ; Tsujimoto, Masayuki ; Ohtani, Hisakazu ; Sawada, Yasufumi. / Pharmacokinetic modelling of the interaction between St John's wort and ciclosporin A. In: British Journal of Clinical Pharmacology. 2006 ; Vol. 61, No. 6. pp. 671-676.
@article{63179fc432e14bdcbe91748a49ccade3,
title = "Pharmacokinetic modelling of the interaction between St John's wort and ciclosporin A",
abstract = "Aims: St John's wort (SJW) decreases the blood concentration of ciclosporin A (CsA), which may result in allograft rejection. In addition, the time course of this interaction is not parallel with the administration of SJW. We aimed to develop a pharmacokinetic model to predict the time profile of blood CsA concentrations during and after the intake of SJW. Methods: We developed a pharmacokinetic model incorporating turnover of detoxicating proteins, with the assumption that the amount of detoxicating proteins is in inverse proportion to the ratio of trough blood concentration to daily dose (C/D ratio) of CsA. First, we collected time profiles of blood CsA during and after the intake of SJW from the literature. Next, we analysed the relationship between D/C ratio and the daily dose of SJW at steady state. Subsequently, the developed model was simultaneously fitted to the time profiles of C/D ratios by using a nonlinear least-squares method to obtain model parameters. Results: The model analysis revealed that the induction of the detoxicating proteins by SJW was saturable with an elimination rate constant of the detoxicating proteins (ke) of 4.72 month-1. Elimination half-life of the detoxicating proteins calculated from the ke value was 4.4 days, suggesting that the dose of CsA should be carefully monitored for up to 2 weeks after the cessation of SJW intake. Conclusions: The present model may provide additional information for use in identifying optimal dosage regimens of CsA during and after the intake of SJW to prevent an adverse drug interaction between CsA and SJW.",
keywords = "Ciclosporin A, Dosage, Drug interaction, Pharmacokinetic model, St John's wort",
author = "Yuichi Murakami and Tomoaki Tanaka and Hideyasu Murakami and Masayuki Tsujimoto and Hisakazu Ohtani and Yasufumi Sawada",
year = "2006",
month = "6",
doi = "10.1111/j.1365-2125.2006.02606.x",
language = "English",
volume = "61",
pages = "671--676",
journal = "British Journal of Clinical Pharmacology",
issn = "0306-5251",
publisher = "Wiley-Blackwell",
number = "6",

}

TY - JOUR

T1 - Pharmacokinetic modelling of the interaction between St John's wort and ciclosporin A

AU - Murakami, Yuichi

AU - Tanaka, Tomoaki

AU - Murakami, Hideyasu

AU - Tsujimoto, Masayuki

AU - Ohtani, Hisakazu

AU - Sawada, Yasufumi

PY - 2006/6

Y1 - 2006/6

N2 - Aims: St John's wort (SJW) decreases the blood concentration of ciclosporin A (CsA), which may result in allograft rejection. In addition, the time course of this interaction is not parallel with the administration of SJW. We aimed to develop a pharmacokinetic model to predict the time profile of blood CsA concentrations during and after the intake of SJW. Methods: We developed a pharmacokinetic model incorporating turnover of detoxicating proteins, with the assumption that the amount of detoxicating proteins is in inverse proportion to the ratio of trough blood concentration to daily dose (C/D ratio) of CsA. First, we collected time profiles of blood CsA during and after the intake of SJW from the literature. Next, we analysed the relationship between D/C ratio and the daily dose of SJW at steady state. Subsequently, the developed model was simultaneously fitted to the time profiles of C/D ratios by using a nonlinear least-squares method to obtain model parameters. Results: The model analysis revealed that the induction of the detoxicating proteins by SJW was saturable with an elimination rate constant of the detoxicating proteins (ke) of 4.72 month-1. Elimination half-life of the detoxicating proteins calculated from the ke value was 4.4 days, suggesting that the dose of CsA should be carefully monitored for up to 2 weeks after the cessation of SJW intake. Conclusions: The present model may provide additional information for use in identifying optimal dosage regimens of CsA during and after the intake of SJW to prevent an adverse drug interaction between CsA and SJW.

AB - Aims: St John's wort (SJW) decreases the blood concentration of ciclosporin A (CsA), which may result in allograft rejection. In addition, the time course of this interaction is not parallel with the administration of SJW. We aimed to develop a pharmacokinetic model to predict the time profile of blood CsA concentrations during and after the intake of SJW. Methods: We developed a pharmacokinetic model incorporating turnover of detoxicating proteins, with the assumption that the amount of detoxicating proteins is in inverse proportion to the ratio of trough blood concentration to daily dose (C/D ratio) of CsA. First, we collected time profiles of blood CsA during and after the intake of SJW from the literature. Next, we analysed the relationship between D/C ratio and the daily dose of SJW at steady state. Subsequently, the developed model was simultaneously fitted to the time profiles of C/D ratios by using a nonlinear least-squares method to obtain model parameters. Results: The model analysis revealed that the induction of the detoxicating proteins by SJW was saturable with an elimination rate constant of the detoxicating proteins (ke) of 4.72 month-1. Elimination half-life of the detoxicating proteins calculated from the ke value was 4.4 days, suggesting that the dose of CsA should be carefully monitored for up to 2 weeks after the cessation of SJW intake. Conclusions: The present model may provide additional information for use in identifying optimal dosage regimens of CsA during and after the intake of SJW to prevent an adverse drug interaction between CsA and SJW.

KW - Ciclosporin A

KW - Dosage

KW - Drug interaction

KW - Pharmacokinetic model

KW - St John's wort

UR - http://www.scopus.com/inward/record.url?scp=33646931750&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33646931750&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2125.2006.02606.x

DO - 10.1111/j.1365-2125.2006.02606.x

M3 - Article

VL - 61

SP - 671

EP - 676

JO - British Journal of Clinical Pharmacology

JF - British Journal of Clinical Pharmacology

SN - 0306-5251

IS - 6

ER -